Navigation Links
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting

WINSTON-SALEM, N.C., June 12, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.

Dr. Bertram will take part in a panel discussion titled "Disease-focused Research: From Bench to Bedside" on Thursday, June 13, 2013 at 11:30am to 12:30pm ET and will cover Tengion's groundbreaking research on the regeneration of the kidney and hollow organs. 

Tengion's platform applies cell-based technologies for tissue and organ regeneration using a patient's own cells.  The company's novel and proprietary technology identifies these cells and uses them to create a neo-organ, with the potential to develop new organs and tissues on a commercial scale.  Tengion has two clinical-stage products including the Neo-Urinary Conduit™ designed to establish a new standard of care for bladder cancer patients undergoing cystectomy and the Neo-Kidney Augment™ intended to delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. 

ISSCR is the largest international interdisciplinary forum dedicated to stem cell science. Shinya Yamanaka, M.D., Ph.D., the current president, was awarded the Nobel Prize for Physiology or Medicine in 2012 for the discovery that adult somatic cells can be reprogrammed to become pluripotent cells capable of developing into all tissues of the body. 

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company initiated a Phase 1 clinical trial in Sweden in May 2013 for the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.


SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
2. Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
3. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
5. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
6. InspireMD To Participate In Benchmark Investor Conference On May 30th
7. ViroPharma To Participate In Two May Healthcare Investor Conferences
8. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
9. AVANIR Pharmaceuticals To participate in two conferences in March
10. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
Breaking Biology Technology:
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):